GENE ONLINE|News &
Opinion
Blog

Anemia
Akebia Therapeutics Gains $55M Following Deal Termination by Otsuka Pharmaceutical
2022-07-04
GSK to Acquire Biopharmaceutical Company Sierra Oncology for $1.9B
2022-04-17
European Commission Approves Global Blood Therapeutics’ Oxbryta for Sickle Cell Disease
2022-02-17
Sanofi’ Enjaymo Wins FDA Approval for Rare Autoimmune Anemia
2022-02-07
Vertex to Reap Majority Profits from Gene Editing Deal with CRISPR Therapeutics
2021-04-21
Bluebird Bio Temporarily Suspends Sickle Cell Trials Following Cancer Diagnosis in Two Patients
2021-02-18
Imara’s Sickle Cell Disease Therapy Impresses in Phase 2 Trial
2021-01-09
GeneOnline’s Top 10 Headlines of the Year
2020-12-30
CRISPR Gene-Edited Therapy CTX001 Raises Hopes for Sickle Cell Disease and β-Thalassemia Cures
2020-12-07
CRISPR, Vertex’s Gene Editing Based Therapy, CTX001 Prospers in Hemoglobinopathy Trials
2020-06-18
Celgene, Acceleron’s novel anemia drug gets FDA green light for rare blood disorder
2019-11-11
LATEST
A New Sequencer on the Horizon – Illumina Genomics Forum Days Two and Three Highlights
2022-09-30
Novo Nordisk Places $700 Million Bet on Ventus’ NLRP3 Inhibitor Program
2022-09-30
Amylyx’s ALS Drug Nabs FDA Nod After Rare Regulatory Reversal
2022-09-29
Illumina Reveals NovaSeq™ X Series at the Illumina Genomics Forum
2022-09-29
Illumina Genomics Forum Kicks Off With A Conversation With President Barack Obama
2022-09-29
First Patient in New Zealand Dosed with Illuccix® – Telix's Prostate Cancer Imaging Agent
2022-09-29
Samsung Biologics introduces new development platforms S-DUAL™ and DEVELOPICK™ at BPI Boston 2022
2022-09-29
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!